Xbrane Biopharma
A biotechnology company specializing in the development of biosimilars.
XBRANE | ST
Overview
Corporate Details
- ISIN(s):
- SE0007789409 (+1 more)
- LEI:
- 5493008DKD05APTKQO39
- Country:
- Sweden
- Address:
- RETZIUS VÄG, 8, 171 65 Solna
- Website:
- https://xbrane.com/en/
- Sector:
- Manufacturing
Description
Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-03-04 09:35 | English | 34.1 KB | |||
| 2021-02-26 08:00 | Swedish | 674.8 KB | |||
| 2021-02-26 08:00 | English | 687.4 KB | |||
| 2021-02-24 08:00 |
To further focus on becoming a world leading biosimilar developer Xbrane enters…
|
English | 69.9 KB | ||
| 2021-02-24 08:00 |
För att fullt ut fokusera på att bli en världsledande utvecklare av biosimilare…
|
Swedish | 71.3 KB | ||
| 2021-01-11 13:30 |
Xbrane appoints Anette Lindqvist as new Chief Financial Officer & Head of Inves…
|
English | 64.4 KB | ||
| 2021-01-11 13:30 |
Xbrane utser Anette Lindqvist till ny Chief Financial Officer & Head of Investo…
|
Swedish | 67.6 KB | ||
| 2021-01-05 08:40 |
Xbrane re-negotiates pre-existing IP license agreement with Vaxiion Therapeutics
|
English | 69.8 KB | ||
| 2021-01-05 08:40 |
Xbrane omförhandlar befintligt patentlicensavtal med Vaxiion Therapeutics
|
Swedish | 70.4 KB | ||
| 2020-12-16 09:00 |
Nina Ivers joins Xbrane Biopharma as Head of HR
|
English | 65.8 KB | ||
| 2020-12-16 09:00 |
Nina Ivers börjar på Xbrane Biopharma som HR-chef
|
Swedish | 66.8 KB | ||
| 2020-11-30 08:00 |
Change of number of shares and votes in Xbrane
|
English | 66.1 KB | ||
| 2020-11-30 08:00 |
Förändrat antal aktier och röster i Xbrane
|
Swedish | 66.9 KB | ||
| 2020-11-16 15:50 |
Xbrane Biopharma publishes a prospectus for admission to trading of shares on N…
|
English | 78.6 KB | ||
| 2020-11-16 15:50 |
Xbrane Biopharma offentliggör prospekt avseende upptagande till handel av aktie…
|
Swedish | 79.8 KB |
Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xbrane Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-17 | Karl Martin Erik Åmark | Other | Buy | 1,864,223 | 318,782.13 SEK |
| 2025-01-17 | Karl Martin Erik Åmark | Other | Sell | 1,864,223 | 315,053.69 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Sell | 1,519,932 | 260,212.36 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Buy | 1,500,000 | 256,500.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Buy | 4,000 | 129,000.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Sell | 4,000 | 128,200.00 SEK |
| 2023-09-11 | Karl Martin Erik Åmark | Other | Sell | 2,000 | 62,140.00 SEK |
| 2023-09-08 | Siavash Bashiri | Other | Sell | 5,890 | 194,959.00 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | 968.54 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | N/A |
Peer Companies
